Legend Biotech (LEGN) Competitors $39.91 -0.23 (-0.57%) (As of 10:31 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends LEGN vs. EIDX, PRNB, AUTL, BLUE, BNTX, TEVA, BGNE, VTRS, MRNA, and SMMTShould you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include Eidos Therapeutics (EIDX), Principia Biopharma (PRNB), Autolus Therapeutics (AUTL), bluebird bio (BLUE), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Moderna (MRNA), and Summit Therapeutics (SMMT). These companies are all part of the "medical" sector. Legend Biotech vs. Eidos Therapeutics Principia Biopharma Autolus Therapeutics bluebird bio BioNTech Teva Pharmaceutical Industries BeiGene Viatris Moderna Summit Therapeutics Eidos Therapeutics (NASDAQ:EIDX) and Legend Biotech (NASDAQ:LEGN) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation. Does the media prefer EIDX or LEGN? In the previous week, Legend Biotech had 28 more articles in the media than Eidos Therapeutics. MarketBeat recorded 28 mentions for Legend Biotech and 0 mentions for Eidos Therapeutics. Legend Biotech's average media sentiment score of 0.07 beat Eidos Therapeutics' score of 0.00 indicating that Legend Biotech is being referred to more favorably in the news media. Company Overall Sentiment Eidos Therapeutics Neutral Legend Biotech Neutral Which has more volatility and risk, EIDX or LEGN? Eidos Therapeutics has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Does the MarketBeat Community favor EIDX or LEGN? Eidos Therapeutics received 66 more outperform votes than Legend Biotech when rated by MarketBeat users. However, 70.80% of users gave Legend Biotech an outperform vote while only 63.20% of users gave Eidos Therapeutics an outperform vote. CompanyUnderperformOutperformEidos TherapeuticsOutperform Votes14663.20% Underperform Votes8536.80% Legend BiotechOutperform Votes8070.80% Underperform Votes3329.20% Which has better valuation & earnings, EIDX or LEGN? Eidos Therapeutics has higher earnings, but lower revenue than Legend Biotech. Eidos Therapeutics is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEidos Therapeutics$26.69M177.99-$37.83M-$1.03-118.65Legend Biotech$285.14M25.66-$518.25M-$0.95-42.25 Do institutionals and insiders believe in EIDX or LEGN? 31.4% of Eidos Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 70.1% of Eidos Therapeutics shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate EIDX or LEGN? Legend Biotech has a consensus price target of $81.46, indicating a potential upside of 102.94%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than Eidos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eidos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Legend Biotech 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is EIDX or LEGN more profitable? Eidos Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -66.92%. Legend Biotech's return on equity of -29.69% beat Eidos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eidos TherapeuticsN/A -65.21% -53.04% Legend Biotech -66.92%-29.69%-19.45% SummaryLegend Biotech beats Eidos Therapeutics on 13 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Legend Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEGN vs. The Competition Export to ExcelMetricLegend BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.00B$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio-42.254.8389.0213.30Price / Sales25.66372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book6.567.876.085.74Net Income-$518.25M$153.61M$119.07M$225.93M7 Day Performance0.63%-2.00%-1.84%-1.32%1 Month Performance-7.62%-7.47%-3.65%0.60%1 Year Performance-29.89%31.80%31.62%26.23% Legend Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEGNLegend Biotech1.7671 of 5 stars$39.82-0.8%$81.46+104.6%-33.7%$7.26B$285.14M-41.921,800Analyst RevisionEIDXEidos TherapeuticsN/A$122.21flatN/AN/A$4.75B$26.69M-118.6570PRNBPrincipia BiopharmaN/A$100.05flatN/AN/A$3.32B$35.16M-47.8765AUTLAutolus Therapeutics3.4801 of 5 stars$2.75-1.8%$10.15+269.1%-36.5%$731.75M$1.70M0.00330Analyst UpgradeBLUEbluebird bio2.4704 of 5 stars$0.30-2.3%$3.03+921.6%-92.1%$57.57M$29.50M-0.16323Analyst ForecastGap UpBNTXBioNTech3.4725 of 5 stars$103.69+1.5%$138.79+33.8%+3.3%$24.86B$4.13B0.006,133Analyst ForecastAnalyst RevisionTEVATeva Pharmaceutical Industries2.7027 of 5 stars$17.11+0.5%$19.67+14.9%+80.0%$19.38B$15.85B-20.0337,851BGNEBeiGene3.1891 of 5 stars$195.49+0.6%$247.07+26.4%+3.4%$19.04B$2.46B-23.5810,600Analyst DowngradeGap UpVTRSViatris1.3514 of 5 stars$13.16+0.2%$13.33+1.3%+38.6%$15.71B$15.43B0.0038,000MRNAModerna4.6292 of 5 stars$36.50-1.2%$84.00+130.1%-53.2%$14.05B$6.85B-6.355,600Analyst UpgradeAnalyst RevisionSMMTSummit Therapeutics1.8779 of 5 stars$18.61-0.1%$34.75+86.7%+835.7%$13.72B$700,000.00-67.00105Analyst Forecast Related Companies and Tools Related Companies EIDX Alternatives PRNB Alternatives AUTL Alternatives BLUE Alternatives BNTX Alternatives TEVA Alternatives BGNE Alternatives VTRS Alternatives MRNA Alternatives SMMT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LEGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LEGN Stock Alerts